ALNA - Allena Pharmaceuticals, Inc.
14.70 0.00 (0.00%)
After hours: 4:59PM EDT
| Previous Close | 14.73 |
| Open | 14.83 |
| Bid | 1.00 x 100 |
| Ask | 15.55 x 2900 |
| Day's Range | 14.56 - 15.50 |
| 52 Week Range | 6.13 - 17.56 |
| Volume | 66,617 |
| Avg. Volume | 88,590 |
| Market Cap | 304.225M |
| Beta | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.80 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.25 |
- Simply Wall St.•6 days ago
Allena Pharmaceuticals Inc (NASDAQ:ALNA): Are Analysts Bull Or Bear?
The most recent earnings announcement Allena Pharmaceuticals Inc’s (NASDAQ:ALNA) released in December 2017 confirmed company earnings became less negative compared to the previous year’s level – great news for investorsRead More...
- Zacks•22 days ago
Allena Pharmaceuticals (ALNA) Enters Overbought Territory
Allena Pharmaceuticals, Inc. (ALNA) has moved higher as of late, but there could definitely be trouble on the horizon for this company
- Motley Fool•27 days ago
3 Biotech Stocks That Soared This Week: Are They Buys?
Can these hot stocks keep the momentum going?
- GlobeNewswire•last month
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
--Initiated URIROX-1™, First Phase 3 Trial of ALLN-177 in Enteric Hyperoxaluria; Topline Data Expected in Second Half of 2019–. --Initiated Phase 2 Trial of ALLN-177 for Patients with Primary Hyperoxaluria ...
- GlobeNewswire•2 months ago
Allena Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference
NEWTON, Mass., March 07, 2018-- Allena Pharmaceuticals, Inc., a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat ...
- GlobeNewswire•2 months ago
Allena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric Hyperoxaluria
URIROX-1 TM is the Largest Controlled Trial of a Novel Therapeutic for this Underserved Patient Population- Topline Data Expected in Second Half of 2019- ALLN-177 has Potential to be the First FDA-Approved ...
- Simply Wall St.•2 months ago
Who Are The Top Investors In Allena Pharmaceuticals Inc (NASDAQ:ALNA)?
In this article, I’m going to take a look at Allena Pharmaceuticals Inc’s (NASDAQ:ALNA) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
- GuruFocus.com•2 months ago
Pharmstandard International S.A. Buys Allena Pharmaceuticals Inc
Investment company Pharmstandard International S.A. buys Allena Pharmaceuticals Inc during the 3-months ended 2017-12-31, according to the most recent filings of the investment company, Pharmstandard International ...
- GlobeNewswire•3 months ago
Allena Pharmaceuticals, Inc. (Nasdaq: ALNA) to Ring The Nasdaq Stock Market Opening Bell
What: Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and ...
- Simply Wall St.•5 months ago
What Is The Future Prospect For Healthcare And Allena Pharmaceuticals Inc (ALNA)?
Allena Pharmaceuticals Inc (NASDAQ:ALNA), a USD$261.28M small-cap, is a healthcare company operating in an industry, which faces demand for new drug development to meet new or persistent chronic illnesses, andRead More...
- Simply Wall St.•6 months ago
Allena Pharmaceuticals Inc (ALNA): Time For A Financial Health Check
Investors are always looking for growth in small-cap stocks like Allena Pharmaceuticals Inc (NASDAQ:ALNA), with a market cap of USD $238.80M. However, an important fact which most ignore is: howRead More...
